

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/49990</b> <b>(43) International Publication Date:</b> 31 August 2000 (31.08.00)
<b>(21) International Application Number:</b> PCT/IN00/00008 <b>(22) International Filing Date:</b> 2 February 2000 (02.02.00) <b>(30) Priority Data:</b> 90/BOM/99 3 February 1999 (03.02.99) IN <b>(71)(72) Applicant and Inventor:</b> KHAMAR, Bakulesh, Mafatlal [IN/IN]; 201 "Ashadha", Vasundhara Colony, Gulbai Tekra, Ellisbridge, Ahmedabad 380 006, Gujarat (IN).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, ID, IL, IS, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MX, NO, PL, RO, SG, SI, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> THE PROCESS FOR MANUFACTURING TOPICAL OPHTHALMIC PREPARATIONS WITHOUT SYSTEMIC EFFECTS		
<b>(57) Abstract</b> <p>For treating eye diseases, various kinds of medications are used. They are used in form of topical preparations or in form of systemic preparations to be taken orally or parenterally. Of topical preparations some are for topical use only e.g. framycetin, neomycin, loteprednol ebanoate, etc. However, large majority of topical ophthalmic drugs are for systemic use also, e.g.. Ciprofloxacin, Gentamicin, Timolol, Clonidine, Dexamethasone, Betamethasone, Carbachol, etc. Some of these drugs when used topically are also found to have systemic effects and if they are of serious nature limits the use of that drug, e.g. cardiopulmonary effects of B-blockers like timolol. Dryness of mouth, flush, fever, tachy cardia, urinary retention, convulsion irritability with atropine. Hypertension with phenylephrine. Increased salivation, nausea, vomiting, diarrhea, stomach cramps, bronchial secretions, bronchial constriction, asthma, bradycardia, paresthesia with miotics, Hypotension with clonidine. Dry mouth, fatigue and drowsiness with apraclonidine and brimonidine.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## THE PROCESS FOR MANUFACTURING TOPICAL OPHTHALMIC PREPARATIONS WITHOUT SYSTEMIC EFFECTS.

The present invention relates to the process for manufacturing topical ophthalmic preparations without systemic effects. Many topical ophthalmic preparations have systemic effects. These systemic effects are responsible for contraindications, side effects, toxicity of some of the topical ophthalmic preparations. Similarly, due to systemic effects certain topical ophthalmic preparations have not been commercialized.

The present invention is directed to manufacturing topical ophthalmic preparations in such a way that systemic effects of that topical ophthalmic preparation do not manifest.

Topical ophthalmic preparations can be divided into two groups. One of the group includes preparations in which active ingredients are for topical use only and have no systemic effects. These group of drugs include antibiotics like Framycetin, Neomycin, Fucidin, steroids like Loteprednol Ebanoate, Triamcinolone, alpha agonist like Apraclonidine, Brimonidine, etc. The other group of topical ophthalmic preparations have active ingredients which are generally used for their effects. These group of preparations include antibiotics like Ciprofloxacin, Norfloxacin, Ofloxacin, Gentamicin, Tobramycin, steroids like Dexamethasone, Betamethasone,  $\beta$ -blockers like Timolol, Betaxolol, etc. Some of these drugs when used topically are also found to have systemic effects. When systemic effects are serious in nature, it results in limiting the use of a drug in the form of contraindication or amount of drug to be used.

Examples of well known systemic effects of topical ophthalmic preparations include cardiopulmonary effects of  $\beta$ -blockers like Timolol, Levobunolol, Metipranolol, Carteolol, etc. Dryness of mouth, flush, fever, tachycardia, urinary retention, convulsion irritability are found with Atropine eye drops. Systemic hypertension is associated with topical mydriatic phenylephrine. Increased salivation, nausea, vomiting, diarrhoea, stomach cramp, bronchial secretions, bronchial constriction, asthma, bradycardia, parasthesia is seen with miotics. Systemic hypotension is main limiting factor for use of clonidine in management of glaucoma. Dry mouth, fatigue and drowsiness seen with Brimonidine and Apraclonidine are some of their systemic effects.

The systemic side effects manifesting with the use of topical ophthalmic preparations results in discontinuation of therapy or not initiating a therapy or reducing the amount of drug or drug not having wide spread acceptance.

Because of this reason, attempts are made to reduce systemic effects of topically applied drugs.

Systemic effects are due to plasma concentration of a drug. It depends on absorption of the drug from conjunctiva or nasal mucosa into systemic circulation (serum levels of drug).

The mechanisms to reduce plasma concentration of a drug includes reduction in drop size. It reduces the amount of drug available through conjunctiva as well as nasal mucosa.

The blockage of nasolacrimal duct temporarily or permanently also reduces drug reaching to nasal mucosa through nasolacrimal passages and thus reduces the amount of drug available systemically. Increasing the viscosity of a formulation also reduces the plasma concentration of a drug. Slow release of a drug through sustained release mechanism/device are known to reduce plasma concentration of topical ophthalmic preparations. Including vasoconstrictive agents into a topical ophthalmic preparation also reduces the plasma level of topically applied drugs.

The other mechanism used to reduce systemic effects include use of a prodrug as topical ophthalmic preparation which gets converted to active compound only at the site of action, e.g. Dipivetrin for epinephrine and Phenylephrine Oxazoline for Phenylephrine.

The other mechanism known includes formulating a preparation as an ointment. The tear film formed with the use of ointment is thick, with poor light transmission and irregular anterior surface. This results in blurring of vision and so have not been popular. It also causes stickiness of lashes and lid margin. This limits its use to a great extent and whenever used, its use is restricted for bed time application.

None of the above described methods in isolation or in combination with each other have been successful in eliminating systemic effects of topical ophthalmic preparations. Majority of efforts are centered around topical  $\beta$ -blockers to reduce their systemic effect, e.g. reduction in pulse rate. All known methods have been able to decrease the reduction in pulse rate, but none of them have been able to eliminate it completely.

## REFERENCES:

1. A Ludwig, N Unlu and M Van Ooteghem.  
Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans.  
International Journal of Pharmaceutics 1990; 61: 15-25.
2. Arto Urtti, James D Pipkin, Gerald Rork, Toshiaki Sendo, Ulha Finne and AJ Repta.  
Controlled drug delivery devices for experimental ocular studies with timolol. 2. Ocular and systemic absorption in rabbits.  
International Journal of Pharmaceutics 1990; 61: 241-249.
3. Benedetto DA, Shah DO, Kaufman HE.  
The instilled fluid dynamics and surface chemistry of polymers in the precocular tear film.  
Invest Ophthalmol 1975 Dec; 14(12): 887-902.
4. Chang SC, Lee VH.  
Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximise the ratio of ocular to systemic absorption.  
J Ocular Pharmacol 1987 Summer; 3(2): 159-69.
5. Chiang CH, Ho JJ, Chen JL.  
Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes.  
J Ocul Pharmacol Ther 1996 Winter; 12(4): 471-80.
6. Jarvinen K, Urtti A.  
Cardiac effects of different eyedrop preparations of timolol in rabbits.  
Curr Eye Res 1992 May; 11(5): 469-73.

7. Johansen S, Rask-Pedersen E, Prause JU.  
A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as a aqueous suspension.  
Acta Ophthalmol Scand 1996 June; 74(3): 253-8
8. Johansen S, Rask-Pedersen E, Prause JU.  
An ocular bioavailability comparison in rabbits of prednisolone acetate after repeated topical applications formulated as a high-viscosity gel and as an aqueous suspension.  
Acta Ophthalmol Scand 1996 June; 74(3): 259-64.
9. Kumar V, Schoenwald RD, Barcellos WA, Chien DS, Folk JC, Weingeist TA.  
Aqueous vs viscous phenylephrine. I. Systemic absorption and cardiovascular effects.  
Arch Ophthalmol 1986 Aug; 104(8): 1189-91.
10. Kumar S, Himmelstein KJ.  
Modification of in situ gelling behaviour of carbopol solutions by hydroxypropyl methyl cellulose.  
J Pharm Sci 1995 Mar; 84(3): 344-8.
11. Kyyronen K, Urtti A.  
Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.  
Invest Ophthalmol Vis Sci 1990 Sep; 31(9): 1827-33.
12. Marco F Saetonne, Patrizia Chetoni, Maria Tilde Torracca, Susi Burgalassi and Boris Giannaccini.  
Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid.  
International Journal of Pharmaceutics 1989; 59: 203-212.

13. Romanelli L, Valeri P, Morrone LA, Pimpinella G, Graziani G, Tita B.  
Ocular absorption and distribution of benzadac after topical administration to rabbits with different vehicles.  
Life Sci 1994; 54(13): 877-85.
14. Sieradzki E.  
Bioavailability of drugs applied to the eye externally [Article in Polish].  
Klin Oczna 1991 jan; 93(1): 34-6.
15. Urtti A.  
Delivery of antiglaucoma drugs: ocular vs systemic absorption.  
J Ocular Pharmacol 1994 Spring; 10(1): 349-57.
16. Urtti A, Salminen L.  
Minimizing systemic absorption of topically administered ophthalmic drugs.  
Surv Ophthalmol 1993 May-June; 37(60): 435-56.
17. van der Ohe N, Stark M, Mayer H, Brewitt H.  
How can the bioavailability of timolol be enhanced? A pharmacokinetic pilot study of novel hydrogels.  
Graefes Arch Clin Exp Ophthalmol 1996 July; 234(7): 452-6.
18. Wilson CG, Olejnik O, Hardy JG.  
Precorneal drainage of polyvinyl alcohol solutions in the rabbit assessed by gamma scintigraphy.  
J Pharm Pharmacol 1983 July; 35(7): 451-54.



The objective of present invention is to provide topical ophthalmic preparations without systemic effects without reducing the concentration of active ingredient.

The further objective of present invention is to provide topical ophthalmic preparations which does not cause significant visual disturbances to limit its use during waking hours.

The further objective of present invention is to provide topical ophthalmic preparations which are equally effective after longer period of storage.

The further objective of present invention is to provide topical ophthalmic preparations which do not require special storage conditions.

Accordingly there is provided a process of manufacturing topical ophthalmic preparations without systemic side effects which comprises of the following steps.

1. Liquid formulation of a selected drug is prepared which contains excipients buffers and preservatives in distilled water. The pH of this solution is adjusted to provide stable formulation for topical ophthalmic use.
2. In a separate vessel polymer is dissolved into a solvent preferably water and stirred well till gel is formed.
3. Solution containing selected drug as formulated in step 1 is gradually added to the gel as formed in step 2.

4. Volume is made up by adding distilled water/solvent as required.
5. pH is checked and adjusted as necessary to provide stable formulation for topical instillation into eye.

The drug described above can be any of the existing ophthalmic preparations or any other drug which cannot be used as a topical preparation in a desired concentration for instillation into eye. The drugs which are most frequently used and are known to have systemic effects include  $\beta$ -blockers like Timolol, Levobunolol, Metipranalol, etc.

Similarly, mydriatics like phenylephrine, atropine, cyclopentolate, tropicamide have systemic effects and their use is restricted by it.

Clonidine is an example of a drug which lowers I.O.P. significantly but cannot be used as 0.1% or 0.2% concentration due to its systemic hypotensive effect.

The polymer to be used for preparing topical formulation as per present invention should form a gel when solubilized. For the purpose of present invention it is desirable to select a polymer with mucoadhesive properties. To avoid discomfort and visual disturbances associated with use of viscous solutions, it is desirable that polymer selected demonstrates pseudoplastic behaviour in a formulation.

Polymer to be used for the purpose of present invention having above properties are known and includes polyacrylic acid, polyacrylic esters, polycarbophile, polyvinyl Acetate, Acrypol, Xantham gum, Guar gum, hydroxy ethyl cellulose, polyvinyl alcohol, PVP, carbomers, hydrogels prepared by combination of various polymers etc. Names of above polymer exemplifies the process and are not restricted to for the purpose of invention.

For the purpose of avoiding systemic effects of a formulation prepared as per present invention, it is necessary to have viscosity above 100,000 cps (one hundred thousand cps), preferably above 400,000 (four hundred thousand cps).

The final volume adjustment and amount of polymer to be used has to be designed considering these requirements. The amount of polymer in a final formulation to get desired viscosity is variable but is well known. It varies with polymer to polymer and also with molecular weight of some polymer.

Pharmaceutical preparations so manufactured can be sterilized by known methods of sterilizing, including autoclaving. If sterilization process is likely to result in unstabilization of drug, it can be prepared as a sterile product throughout the process.

## Examples of formulations

### I. Timolol

#### A.. Timolol 0.5%

Timolol Maleate	0.72 gm. equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Polyacrylic Acid (Carbopol 940)	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	QS to make 100 ml.

#### B. Timolol 0.25%

Timolol Maleate	0.36 gm equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Polyacrylic Acid (Carbopol 940)	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	QS to make 100 ml

### II. Timolol

#### A.. Timolol 0.5%

Timolol Maleate	0.72 gm. equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Carbopol ETD 2001	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml.

#### B. Timolol 0.25%

Timolol Maleate	0.36 gm equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Carbopol ETD 2001	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml

### III. Timolol

#### A.. Timolol 0.5%

Timolol Maleate	0.72 gm. equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Carbopol 981	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml.

**B. Timolol 0.25%**

Timolol Maleate	0.36 gm equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Carbopol 981	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml

**IV. Timolol****A.. Timolol 0.5%**

Timolol Maleate	0.72 gm. equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Polycarbophil	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml.

**B. Timolol 0.25%**

Timolol Maleate	0.36 gm equivalent to 0.5 gm of Timolol
Benzylconium chloride	0.0107 gm
Polycarbophil	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml

**V. Clonidine****A. Clonidine 0.1%**

Clonidine hydrochloride	0.1 gm
Benzylconium chloride	0.0107 gm
Polyacrylic Acid (Carbopol 940)	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	QS to make 100 ml

**B. Clonidine 0.2%**

Clonidine hydrochloride	0.2 gm
Benzylconium chloride	0.0107 gm
Polyacrylic Acid (Carbopol 940)	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	QS to make 100 ml

**VI. Clonidine****A. Clonidine 0.1%**

Clonidine hydrochloride . 0.1 gm  
Benzylconium chloride 0.0107 gm  
Carbopol ETD 2001 1.5 gm to 2.5 gm  
Sodium hydroxide to adjust pH 6.5 to 7.5  
Water for injection Q.S. to make 100 ml

**B. Clonidine 0.2%**

Clonidine hydrochloride 0.2 gm  
Benzylconium chloride 0.0107 gm  
Carbopol ETD 2001 1.5 gm to 2.5 gm  
Sodium hydroxide to adjust pH 6.5 to 7.5  
Water for injection Q.S. to make 100 ml

**VII. Clonidine****A. Clonidine 0.1%**

Clonidine hydrochloride 0.1 gm  
Benzylconium chloride 0.0107 gm  
Carbopol 981 1.5 gm to 2.5 gm  
Sodium hydroxide to adjust pH 6.5 to 7.5  
Water for injection Q.S. to make 100 ml

**B. Clonidine 0.2%**

Clonidine hydrochloride 0.2 gm  
Benzylconium chloride 0.0107 gm  
Carbopol 981 1.5 gm to 2.5 gm  
Sodium hydroxide to adjust pH 6.5 to 7.5  
Water for injection Q.S. to make 100 ml

**VIII. Clonidine****A. Clonidine 0.1%**

Clonidine hydrochloride	0.1 gm
Benzylconium chloride	0.0107 gm
Polycarbophil	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml

**B. Clonidine 0.2%**

Clonidine hydrochloride	0.2 gm
Benzylconium chloride	0.0107 gm
Polycarbophil	1.5 gm to 2.5 gm
Sodium hydroxide to adjust pH	6.5 to 7.5
Water for injection	Q.S. to make 100 ml

**IX. Betaxolol****Betaxolol 0.5%**

Betaxolol hydrochloride	0.56 gm. equivalent to 0.5 gm of Betaxolol
Benzylconium chloride	0.01 gm
Dibasic sodium phosphate	0.05 gm
Sodium phosphate monobasic	0.025 gm
Disodium EDTA	0.05 gm
Sodium chloride	0.3 gm
Propylene glycol	2.5 gm
Carbopol ETD 2001	2.0 gm
Water for injection	Q.S. to make 100 ml.

**X. Betaxolol**

Betaxolol 0.5%

Betaxolol hydrochloride 0.56 gm. equivalent to 0.5 gm of Betaxolol

Benzylconium chloride 0.01 gm

Dibasic sodium phosphate 0.05 gm

Sodium phosphate monobasic 0.025 gm

Disodium EDTA 0.05 gm

Sodium chloride 0.3 gm

Propylene glycol 2.5 gm

Polyacrylic acid 2.0 gm

(Carbopol 940)

Water for injection Q.S. to make 100 ml

**X.I Betaxolol**

Betaxolol 0.5%

Betaxolol hydrochloride 0.56 gm. equivalent to 0.5 gm of Betaxolol

Benzylconium chloride 0.01 gm

Dibasic sodium phosphate 0.05 gm

Sodium phosphate monobasic 0.025 gm

Disodium EDTA 0.05 gm

Sodium chloride 0.3 gm

Propylene glycol 2.5 gm

Carbopol 981 2.0 gm

Water for injection Q.S. to make 100 ml.

**XI.I. Betaxolol**

Betaxolol 0.5%

Betaxolol hydrochloride 0.56 gm. equivalent to 0.5 gm of Betaxolol

Benzylconium chloride 0.01 gm

Dibasic sodium phosphate 0.05 gm

Sodium phosphate monobasic 0.025 gm

Disodium EDTA 0.05 gm

Sodium chloride 0.3 gm

Propylene glycol 2.5 gm

Polycarbophil 2.0 gm

Water for injection Q.S. to make 100 ml.



Pharmaceutical composition so manufactured is evaluated for stability and efficacy.

The Pharmaceutical composition so manufactured is evaluated at different test conditions of temperature and humidity (as per ICH guidelines, 40°C/75% RH, 25°C/60% RH) for time interval extending upto 12 months.

The samples of formulations so prepared were used for study.

The topical ophthalmic preparation of Clonidine 0.1% and 0.2% so prepared were evaluated in vivo studies.

Healthy normal volunteers (10) had instillation of drug in their eyes. I.O.P. and B.P. were measured every 2 hours. Control group (10) received placebo.

Drop in I.O.P. was seen only in eyes receiving Clonidine. It was found to be in the range of 30% of initial I.O.P. The effect on I.O.P. was found to last 8 – 10 hours.

Effect on blood pressure in both groups i.e. Clonidine and placebo was identical for systolic as well as diastolic blood pressure and it was insignificant. Peak reduction in systolic B.P. was 4.4 mm of Hg was for placebo, 4.11 mm of Hg for 0.1% Clonidine and 3.93 mm. of Hg for 0.2% Clonidine. Peak reduction in diastolic B.P. was 4.23 mm of Hg for placebo, 4.49 mm of Hg. for Clonidine 0.1% and 2.89 mm of Hg for Clonidine 0.2%.

Clonidine eye drops even when used at 0.05 % to 0.06 % concentration are associated with reduction in systemic B.P.

The topical ophthalmic preparation of Timolol Maleate 0.5% made according to present invention was evaluated for systemic effects and compared with Timolol eye drops and Timoptic XE.

In healthy normal volunteers (10 in each group) various formulations of Timolol and placebo drug were instilled in both eyes. I.O.P. and resting pulse rate were measured every 2 hours. The peak reduction in mean I.O.P. was 25% with Timolol drops, 27% with Timoptic XE and 40% with Timolol made as per present invention. The change in resting pulse rate was identical in placebo and Timolol as per present invention. It was 13.2% with Timolol drops and 13.33% with Timoptic XE.

Thus, both the preparations of Clonidine as well as Timolol made according to present invention were found to have no systemic effect. The efforts were made to find out plasma concentration of drugs but none of the drugs achieved detectable plasma concentrations.

Thus, present invention provides process for manufacturing of topical ophthalmic preparations without systemic effects.

The above examples of formulations are provided as a proof of working of this invention and should not be restricted to this only. Any drug useful after instillation into eye can be formulated according to present invention without systemic effect.

**I claim :**

1. The process of manufacturing of formulation of topical ophthalmic preparations without systemic effect comprising the following steps.
  - i. Making a gel using polymers with or without physiologically acceptable excipients buffers and preservatives
  - ii. Adding liquid formulation of a drug into a prepared gel of step (i) while stirring slowly.
  - iii. Adjusting the pH and volume before final packing
2. A process as claimed in claim 1 wherein Polymer can be any polymer having pseudoplastic behaviour.
3. A process as claimed in claim 1 & 2 wherein polymer should have mucoadhesive property.
4. A process as claimed in claim 1 to 3 wherein polymer can be but not restricting to Carbopol 940 (Polyacrylic acid), Carbopol ETD 2001, Carbopol 981, Polycarbophil, Polyvinyl Alcohol, Hydroxyethyl-Cellulose, Polyacrylic esters, Acrypol, Xantham gum, Guar gum, poly-vinyl ester, Carbomer etc.
5. Polymer as claimed in claim 1 to 4 can be used alone or in combination with other polymers.

6. The process as claimed in claim 1 to 5 wherein viscosity of final formulation is more than 100,000 cps (One hundred thousand cps).
7. The process as claimed in claim 1 to 6 physiologically acceptable buffers excipients and preservatives are used.
8. The process as claimed in claim 1 to 7 wherein liquid formulation of a drug can be in the form of aqueous solution, suspension or emulsion.
9. The process as claimed in claim 1 to 8 wherein volume of formulation is adjusted to get desired concentration of a drug into final formulation.
10. A process as claimed in claim 1 to 9 and substantially described in example in accompanying specification.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number  
WO 00/49990 A3

- (51) International Patent Classification<sup>7</sup>: A61K 9/08, LC, LK, LR, LS, LT, LV, MG, MK, MN, MX, NO, PL, RO, 47/32, 47/36 SG, SI, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (21) International Application Number: PCT/IN00/00008
- (22) International Filing Date: 2 February 2000 (02.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 90/BOM/99 3 February 1999 (03.02.1999) IN Published: — with international search report
- (71) Applicant and
- (72) Inventor: KHAMAR, Bakulesh, Mafatlal [IN/IN]; 201 "Ashadha", Vasundhara Colony, Gulbai Tekra, Ellisbridge, Ahmedabad 380 006, Gujarat (IN). (88) Date of publication of the international search report: 26 July 2001
- (81) Designated States (national): AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, ID, IL, IS, KP, KR, For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/49990 A3

(54) Title: THE PROCESS FOR MANUFACTURING TOPICAL OPHTHALMIC PREPARATIONS WITHOUT SYSTEMIC EFFECTS

(57) Abstract: The invention relates to topical ophthalmic preparations resp. a process for manufacturing the same using polymers in such a way that they have desired topical effects but no systemic effects. The polymers (e.g. polyacrylic acids, hydroxyethyl cellulose, etc.) used for this purpose have pseudo-plastic, mucoadhesive and viscosity enhancing properties.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IN 00/00008

## CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: A61K 9/08, 47/32, 47/36

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/00887 A1 (LABORATOIRE EUROPHTA S.A.) 21 January 1993 (21.01.93) abstract; page 2, lines 5-13; example 1-9.	1-10
X	DD 294174 A5 (KEIPERT S. et al.) 26 September 1991 (26.09.91) totality.	1-10
X	WO 93/02663 A1 (LABORATOIRES MERCK SHARP & DOHME-CHIBRET) 18 February 1993 (18.02.93)	5
A	page 3, lines 13-20; page 6, lines 16-25; page 7, lines 5-10.	1-4, 6-10
X	EP 0801948 A1 (DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH) 22 October 1997 (22.10.97)	5
A	page 3, lines 24-48; claims.	1-4, 6-10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&amp;“ document member of the same patent family

Date of the actual completion of the international search

27 December 2000 (27.12.2000)

Date of mailing of the international search report

13 February 2001 (13.02.2001)

Name and mailing address of the ISA/AT

Austrian Patent Office

Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

KRENN

Telephone No. 1/53424/435

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IN 00/00008

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
DD	A	294174		none		
EP	A1	801948	22-10-1997	AU	A1	20246/97
				AU	B2	714093
				BR	A	9708669
				CA	AA	2251982
				CN	A	1215988
				DE	A1	19614823
				JP	T2	00508646
				PL	A1	328656
				WO	A1	9738674
WO	A1	9300887	21-01-1993	AT	E	165732
				AU	A1	23605/92
				DE	C0	69225405
				DE	T2	69225405
				EP	A1	594760
				EP	B1	594760
				ES	T3	2118824
				FI	A0	940081
				FI	A	940081
				FR	A1	2678832
				FR	B1	2678832
				NO	A0	940064
				NO	A	940064
WO	A1	9302663	18-02-1993	FR	A1	2679773

